Results 61 to 70 of about 1,005 (173)

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives

open access: yesNature and Science of Sleep, 2021
Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...
Abad VC
doaj  

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Efficacy of Pitolisant 20 mg in Reducing Excessive Daytime Sleepiness and Fatigue in Patients with Obstructive Sleep Apnoea Syndrome: An Individual Patient Data Meta-analysis

open access: yes, 2022
BACKGROUND AND OBJECTIVE: Excessive daytime sleepiness (EDS) and fatigue are major complaints in patients with obstructive sleep apnoea (OSA) syndrome. Pitolisant is an orally active selective histamine H3 receptor (H3R) antagonist/inverse agonist, which
Lehert, P
core   +1 more source

Targeting Histone H3K9 Methyltransferase G9a as a Potential Therapeutic Strategy for Neuropsychiatric Disorders

open access: yesMedicinal Research Reviews, Volume 45, Issue 6, Page 1547-1563, November 2025.
ABSTRACT Neuropsychiatric disorders present a multifaceted challenge, characterized by cognitive, social, and motor impairments with manifold underlying mechanisms. Recent attention has turned to epigenetic mechanisms, particularly histone lysine methyltransferases (HKMTs), such as G9a, in understanding fundamental pathogenesis.
Malak Hajar   +4 more
wiley   +1 more source

Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns

open access: yesNature and Science of Sleep, 2020
Emily C Barker,1 Julie Flygare,2 Shalini Paruthi,3,4 Katherine M Sharkey5– 7 1Case Western Reserve University School of Medicine, Department of Pediatrics, Cleveland, OH, USA; 2Project Sleep, Los Angeles, CA, USA; 3Sleep Medicine and Research ...
Barker EC   +3 more
doaj  

Narcolepsy 2025 (with an Australasian perspective)

open access: yesInternal Medicine Journal, Volume 55, Issue 11, Page 1805-1813, November 2025.
Abstract Narcolepsy is a disorder of central hypersomnolence, which, while uncommon, can carry profound implications for affected individuals. Despite this, it remains under‐recognised within the medical community and presents frequent diagnostic and treatment challenges in the Australasian setting.
Amelia Lin   +3 more
wiley   +1 more source

Recent advances in narcolepsy

open access: yesAdvances in Clinical Neuroscience & Rehabilitation, 2016
Narcolepsy is thought to affect 0.05% of Caucasian populations and frequently causes severe symptoms across the 24-hour period. It is best viewed as a disorder of sleep-wake regulation with particular abnormalities of the rapid eye movement (REM ...
Paul Reading
doaj   +1 more source

Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers

open access: yesBrain and Behavior, Volume 15, Issue 10, October 2025.
Orexin deficiency drives narcolepsy Type 1, leading to excessive daytime sleepiness, cataplexy, and REM intrusions. This review highlights recent advances (2023–2025) in molecular mechanisms, diagnostics, and emerging orexin‐targeted therapies with the potential for disease modification.
Rameesha Rauf   +9 more
wiley   +1 more source

New developments in the management of narcolepsy

open access: yesNature and Science of Sleep, 2017
Vivien C Abad, Christian Guilleminault Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University Outpatient Center, Redwood City, CA, USA Abstract: Narcolepsy is a life-long, underrecognized sleep disorder ...
Abad VC, Guilleminault C
doaj  

Principal component analysis (PCA) plots for HDAC2 conformations in apo, pitolisant-bound and SAHA-bound trajectory frames (coloured from blue to red in order of time).

open access: yes, 2022
PC1 and PC2 collectively account for first 2 eigenvalue ranks with overall variations of 43.98% (Apo), 35.82% (Pitolisant) and 35.76% (SAHA) in HDAC2 structure.
Bikash Medhi (3908917)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy